Free Beyond morphology:FDA mulls acute lymphoblastic leukemia drug based on elimination of “minimal residual disease” March 09, 2018Vol.44 No.10By Paul Goldberg
FreeTrials & Tribulations A phase III trial seeks to determine whether diet and exercise can cure breast cancer March 02, 2018Vol.44 No.09By Jennifer A. Ligibel
Conversation with The Cancer LetterFree PH.AI CEO Hyde: With Big Data, pharma will focus on the measurement of value March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Roche CEO O’Day: Our investment in Flatiron will accelerate their mission March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Free Roche to acquire Flatiron Health for $2.1 billion,with focus on real-world data March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
FreeTrials & Tribulations Diversity within Diversity: Lessons from the Latinos of South Texas February 23, 2018Vol.44 No.08By Amelie G. Ramirez and Ruben A. Mesa
Conversation with The Cancer LetterFree UT Health San Antonio’s link with MD Anderson goes live; How does it work? February 23, 2018Vol.44 No.08By Paul Goldberg
Conversation with The Cancer LetterFree His six-month “listening tour” almost over, Sharpless discusses his vision for NCI February 23, 2018Vol.44 No.08By Paul Goldberg
FreeTrials & Tribulations A Cancer Patient’s War on Cancer February 16, 2018Vol.44 No.07By C. Anthony "Tony" Blau
NCI Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s February 16, 2018Vol.44 No.07
